FY2026 Earnings Forecast for Ocugen Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Ocugen to a loss of $0.22 per share from a projected loss of $0.27; its Q4 2026 estimate is a loss of $0.08 per share. The broader consensus FY estimate is a loss of $0.25 per share.
• Ocugen’s latest reported quarter showed a $0.07-per-share loss, worse than the $0.05 loss analysts expected, while revenue of $1.49 million exceeded the $0.89 million consensus estimate.
• Analyst opinion is mixed: four analysts rate the stock Buy and one rates it Sell, giving Ocugen a “Moderate Buy” consensus and an average price target of $9.50. Shares opened at $0.82 and were down 6.6% in the article’s report.

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Investment analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Ocugen in a note issued to investors on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.22) per share for the year, up from their previous forecast of ($0.27). The consensus estimate for Ocugen's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Ocugen's Q4 2026 earnings at ($0.08) EPS.

Ocugen (NASDAQ:OCGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $1.49 million during the quarter, compared to the consensus estimate of $0.89 million.

A number of other analysts have also weighed in on OCGN. Wall Street Zen lowered shares of Ocugen from a "hold" rating to a "sell" rating in a research note on Saturday, October 24th. Weiss Ratings upgraded shares of Ocugen from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $9.50.

Ocugen Trading Down 6.6%

Shares of OCGN opened at $0.82 on Friday. The stock has a 50-day simple moving average of $0.99 and a 200-day simple moving average of $1.41. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 4.17. Ocugen has a 1 year low of $0.69 and a 1 year high of $2.73.

Institutional Investors Weigh In On Ocugen

Several hedge funds and other institutional investors have recently made changes to their positions in OCGN. Bank of America Corp DE purchased a new stake in shares of Ocugen during the 2nd quarter worth approximately $3,046,000. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Ocugen by 121.7% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 2,830,397 shares of the company's stock valued at $4,331,000 after buying an additional 1,553,672 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Ocugen in the 2nd quarter valued at $41,314,000. Headlands Technologies LLC grew its position in shares of Ocugen by 527.1% in the 2nd quarter. Headlands Technologies LLC now owns 511,575 shares of the company's stock valued at $783,000 after buying an additional 429,997 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Ocugen in the 2nd quarter valued at $1,238,000. Institutional investors and hedge funds own 10.27% of the company's stock.

Insider Transactions at Ocugen

In other Ocugen news, CEO Shankar Musunuri sold 57,264 shares of Ocugen stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $0.95, for a total transaction of $54,400.80. Following the completion of the sale, the chief executive officer directly owned 1,030,771 shares of the company's stock, valued at $979,232.45. The trade was a 5.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,051,982 shares of company stock worth $1,088,801. 3.95% of the stock is owned by insiders.

Ocugen News Summary

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Ocugen’s Q3 revenue exceeded analyst expectations, while its quarterly loss was generally reported as in line with estimates. Coverage linked the results to a sharp rise in the shares. Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
• Positive Sentiment: Management said all three late-stage modifier gene therapy programs have reached Phase 3, with key data readouts expected in 2027. The company is targeting three biologics license application submissions by 2028—important potential milestones for its pipeline. Ocugen Q3 2026 Earnings Call Highlights
• Positive Sentiment: Ocugen reported $84.6 million in cash and highlighted new licensing agreements, including a Middle East deal. Cash provides resources to advance its clinical programs, though future development and regulatory work will require continued funding. Ocugen Q3 2026 Earnings Call Transcript
• Neutral Sentiment: The company remains loss-making. The reported quarterly loss was in line with estimates, so it was not an obvious negative surprise, but Ocugen’s investment case continues to depend on clinical progress and eventual commercialization. Ocugen Reports Q3 Loss, Tops Revenue Estimates

Ocugen Company Profile

Ocugen, Inc NASDAQ: OCGN is a biotechnology company focused on developing gene and cell therapies for blindness diseases and vaccines for infectious diseases. The company's programs are designed to address serious conditions with limited treatment options, including inherited retinal diseases and diseases affecting the central retina.

Ocugen's pipeline includes modifier gene therapy candidates intended to treat multiple retinal disorders with a single therapeutic approach. Its lead programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.